| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0014-2999(92)90023-W |
| P698 | PubMed publication ID | 1356787 |
| P50 | author | Efrain C Azmitia | Q40226267 |
| P2093 | author name string | Gu XF | |
| Berger UV | |||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluoxetine | Q422244 |
| P304 | page(s) | 153-160 | |
| P577 | publication date | 1992-05-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine | |
| P478 | volume | 215 |
| Q34565712 | 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings |
| Q43581726 | 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. |
| Q36834482 | 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats |
| Q36834486 | 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats |
| Q24680216 | 5‐HT loss in rat brain following 3, 4‐methylenedioxymethamphetamine (MDMA), p‐chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine |
| Q72549646 | 6-Fluoro-serotonin as a substrate for the neuronal serotonin transporter |
| Q44300538 | A brain microdialysis study on 5-HT release in freely moving rat lines selectively bred for differential 5-HT1A receptor function |
| Q34476901 | A comprehensive review of MDMA and GHB: two common club drugs |
| Q37012610 | Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons |
| Q35745285 | Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function |
| Q89231003 | Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys |
| Q40646803 | Administration of fenfluramine at different ambient temperatures produces different core temperature and 5-HT neurotoxicity profiles |
| Q48367276 | Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans |
| Q62965009 | Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil |
| Q35026544 | Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. |
| Q41694692 | Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners |
| Q36020276 | Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy |
| Q34544993 | Decision-making in chronic ecstasy users: a systematic review. |
| Q43880284 | Differential involvement of 5-HT(2A) receptors in the discriminative-stimulus effects of cocaine and methamphetamine |
| Q31680561 | Differential sensitivities to the lethal, but not the neurotoxic, effects of p-chloroamphetamine in inbred rat strains |
| Q43635684 | Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine |
| Q28548147 | Effect of MDMA-Induced Axotomy on the Dorsal Raphe Forebrain Tract in Rats: An In Vivo Manganese-Enhanced Magnetic Resonance Imaging Study |
| Q46772851 | Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain |
| Q38372945 | Endogenous 5-HT outflow from chicken aorta by 5-HT uptake inhibitors and amphetamine derivatives. |
| Q43572918 | Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate |
| Q37705731 | Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates |
| Q48367827 | Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats. |
| Q34359604 | Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research |
| Q34528465 | Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research |
| Q44112608 | Impaired spatial and sequential learning in rats treated neonatally with D-fenfluramine |
| Q48428396 | In vivo correlates of central serotonin function after high-dose fenfluramine administration |
| Q72483586 | Influence of naloxone upon motor activity induced by psychomotor stimulant drugs |
| Q84586372 | Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D |
| Q46857178 | Initial deficit and recovery of function after MDMA preexposure in rats |
| Q42447539 | Iontophoresis of amphetamine in the neostriatum and nucleus accumbens of awake, unrestrained rats |
| Q34303948 | Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity |
| Q40362823 | MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. |
| Q48371859 | Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output |
| Q34086076 | Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addiction |
| Q30435613 | Methamphetamine-induced behavioral sensitization in a rodent model of posttraumatic stress disorder |
| Q73371204 | Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q43543797 | Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs. |
| Q34976260 | Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. |
| Q34360861 | N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). |
| Q24619949 | Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA) |
| Q44865152 | Neurotoxicity of methamphetamine and methylenedioxymethamphetamine |
| Q37800812 | Presynaptic control of serotonin on striatal dopamine function |
| Q35737059 | Pulmonary hypertension as a result of drug therapy |
| Q73065128 | Rat strain differences in the vulnerability of serotonergic nerve endings to neurotoxic damage by p-chloroamphetamine |
| Q30946517 | Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice |
| Q52170975 | Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA. |
| Q34117810 | Serotonin releasing agents. Neurochemical, therapeutic and adverse effects |
| Q33652473 | Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(±)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats |
| Q28138124 | Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity |
| Q74238250 | Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine |
| Q73466644 | Supraadditive effect of d-fenfluramine plus phentermine on extracellular acetylcholine in the nucleus accumbens: possible mechanism for inhibition of excessive feeding and drug abuse |
| Q41427028 | The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells |
| Q48149811 | The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain |
| Q44454418 | The effects of dentate granule cell destruction on behavioral activity and Fos protein expression induced by systemic MDMA in rats |
| Q50921579 | The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. |
| Q38118305 | The effects of locus coeruleus and norepinephrine in methamphetamine toxicity |
| Q28346708 | The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain |
| Q35754068 | The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study |
| Q21558652 | The neurotoxicity of amphetamines during the adolescent period |
| Q28344876 | The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats |
| Q34281043 | The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum |
| Q34112933 | The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives |
| Q51971591 | The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. |
| Q37051381 | The skin as a mirror of the soul: exploring the possible roles of serotonin. |
| Q34142899 | Therapeutic and adverse actions of serotonin transporter substrates |
| Q22252794 | Toxicity of amphetamines: an update |
| Q33864810 | Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. |
Search more.